Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immuron Ltd ADR
(NQ:
IMRN
)
2.770
+0.050 (+1.84%)
Streaming Delayed Price
Updated: 2:39 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immuron Ltd ADR
< Previous
1
2
Next >
Immuron CEO, Steven Lydeamore to present at Bioshares
July 24, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Business Update - Ateria Health launches Juvia™ in Australia
July 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron FY23 Sales increase 136% on FY22 Sales
July 05, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Chairman Transition
June 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Business Update: Letter to Shareholders
June 22, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Initiates Recruitment of Travelan® Clinical Study
May 30, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Announces FDA Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves way for Clinical Trial Initiation
May 08, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at Coffee Microcaps
May 02, 2023
From
Immuron Limited
Via
GlobeNewswire
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
May 09, 2023
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which...
Via
FinancialNewsMedia
Topics
Intellectual Property
Exposures
Intellectual Property
Immuron Q3 FY23 Business Update Presentation
April 19, 2023
From
Immuron Limited
Via
GlobeNewswire
Q3 FY23 Business Update Webinar Notification
April 11, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Q3 Sales reach 150% of 1H Sales
April 06, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to host an investor webinar
February 15, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic
January 25, 2023
From
Immuron Limited
Via
GlobeNewswire
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment Milestone
January 18, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated Disease
January 17, 2023
From
Immuron Limited
Via
GlobeNewswire
Immuron Receives FDA Approval for Travelan IND Application
December 23, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron Submits IND Application To FDA for Travelan
December 05, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron completes strategic investment in leading gut health biotech Ateria Health
November 16, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron CEO, Steven Lydeamore to present at AusBioInvest
October 26, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron strategic investment in leading gut health biotech Ateria Health
October 13, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron Executes Travelan Clinical Trial Agreement with US-based Pharmaron
October 04, 2022
From
Immuron Limited
Via
GlobeNewswire
Immuron US DoD Naval Medical Research Center Receives feedback on IND Application for New Campylobacter ETEC Therapeutic
July 26, 2022
From
Immuron Limited
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.